IL145163A0 - Methods and compositions using (-) norcisapride in combination with proton pump inhibitors or h2 receptor antagonists - Google Patents
Methods and compositions using (-) norcisapride in combination with proton pump inhibitors or h2 receptor antagonistsInfo
- Publication number
- IL145163A0 IL145163A0 IL14516300A IL14516300A IL145163A0 IL 145163 A0 IL145163 A0 IL 145163A0 IL 14516300 A IL14516300 A IL 14516300A IL 14516300 A IL14516300 A IL 14516300A IL 145163 A0 IL145163 A0 IL 145163A0
- Authority
- IL
- Israel
- Prior art keywords
- norcisapride
- compositions
- methods
- combination
- receptor antagonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12239399P | 1999-03-02 | 1999-03-02 | |
PCT/US2000/005167 WO2000051584A2 (en) | 1999-03-02 | 2000-03-01 | Methods and compositions using (-) norcisapride in combination with proton pump inhibitors or h2 receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
IL145163A0 true IL145163A0 (en) | 2002-06-30 |
Family
ID=22402453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14516300A IL145163A0 (en) | 1999-03-02 | 2000-03-01 | Methods and compositions using (-) norcisapride in combination with proton pump inhibitors or h2 receptor antagonists |
Country Status (21)
Country | Link |
---|---|
US (2) | US6362202B1 (xx) |
EP (1) | EP1156853A2 (xx) |
JP (1) | JP2002538104A (xx) |
KR (1) | KR20010108299A (xx) |
CN (1) | CN1399572A (xx) |
AR (1) | AR022811A1 (xx) |
AU (1) | AU3710800A (xx) |
BG (1) | BG105932A (xx) |
BR (1) | BR0008664A (xx) |
CA (1) | CA2362488A1 (xx) |
CO (1) | CO5150222A1 (xx) |
EA (1) | EA200100937A1 (xx) |
EE (1) | EE200100459A (xx) |
HU (1) | HUP0200151A3 (xx) |
IL (1) | IL145163A0 (xx) |
NO (1) | NO20014229L (xx) |
NZ (1) | NZ513967A (xx) |
PL (1) | PL350862A1 (xx) |
SK (1) | SK12342001A3 (xx) |
TR (1) | TR200103128T2 (xx) |
WO (1) | WO2000051584A2 (xx) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6353005B1 (en) * | 1999-03-02 | 2002-03-05 | Sepracor, Inc. | Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist |
US6362202B1 (en) * | 1999-03-02 | 2002-03-26 | Sepracor Inc. | Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists |
US6821285B2 (en) | 1999-06-22 | 2004-11-23 | Ndo Surgical, Inc. | Tissue reconfiguration |
US6663639B1 (en) * | 1999-06-22 | 2003-12-16 | Ndo Surgical, Inc. | Methods and devices for tissue reconfiguration |
US6835200B2 (en) | 1999-06-22 | 2004-12-28 | Ndo Surgical. Inc. | Method and devices for tissue reconfiguration |
US7846180B2 (en) | 1999-06-22 | 2010-12-07 | Ethicon Endo-Surgery, Inc. | Tissue fixation devices and methods of fixing tissue |
US8287554B2 (en) * | 1999-06-22 | 2012-10-16 | Ethicon Endo-Surgery, Inc. | Method and devices for tissue reconfiguration |
WO2002026210A2 (en) * | 2000-09-29 | 2002-04-04 | Geneva Pharmaceuticals Inc. | Proton pump inhibitor formulation |
WO2002041918A2 (en) * | 2000-11-24 | 2002-05-30 | Janssen Pharmaceutica N.V. | Use of a triple combination comprising a 5ht3 antagonist, a 5ht4 agonist and a laxative for promoting intestinal lavage |
US20040048874A1 (en) * | 2001-05-22 | 2004-03-11 | Bardsley Hazel Judith | New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine |
GB0216027D0 (en) | 2002-07-10 | 2002-08-21 | Arachnova Therapeutics Ltd | New therapeutic use |
AU2002365936A1 (en) * | 2001-11-16 | 2003-09-02 | Eisai Co. Ltd | Compositions and methods to treat gastrointestinal disorders |
AU2002366796A1 (en) * | 2001-12-19 | 2003-07-09 | Eisai Co. Ltd | Methods using proton pump inhibitors |
AU2003241464A1 (en) * | 2002-05-17 | 2003-12-02 | Eisai Co., Ltd. | Compositions and methods using proton pump inhibitors |
US20030228363A1 (en) * | 2002-06-07 | 2003-12-11 | Patel Mahendra R. | Stabilized pharmaceutical compositons containing benzimidazole compounds |
WO2004024192A1 (en) * | 2002-09-12 | 2004-03-25 | University Of Chicago | Monitoring and diagnosis of gastric emptying and gastroparesis |
FR2845916B1 (fr) * | 2002-10-21 | 2006-07-07 | Negma Gild | Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l'histamine |
SE0203410D0 (sv) * | 2002-11-18 | 2002-11-18 | Astrazeneca Ab | New use |
KR20050094843A (ko) * | 2003-01-13 | 2005-09-28 | 다이노젠 파마세우티컬스, 인코포레이티드 | 욕지기, 구토, 구역질 또는 이들의 조합을 치료하는 방법 |
AU2004204825B2 (en) * | 2003-01-13 | 2007-07-19 | Dynogen Pharmaceuticals, Inc. | Method of treating functional bowel disorders |
US20040192781A1 (en) * | 2003-03-31 | 2004-09-30 | Haley Eugene T. | Method of administration for metoclopramide and pharmaceutical formulation therefor |
WO2004089414A2 (en) * | 2003-04-08 | 2004-10-21 | Medley S.A. Indústria Farmacêutica | Combinations of proton pump inhibitors or blockers with prokinetic agents |
JP2007507425A (ja) * | 2003-08-29 | 2007-03-29 | ダイノゲン ファーマシューティカルズ,インコーポレイテッド | 胃腸管運動障害を処置するために有用な組成物 |
WO2006011159A2 (en) * | 2004-06-21 | 2006-02-02 | Torrent Pharmaceuticals Limited | Stabilized pharmaceutical composition containing rabeprazole sodium with improved bioavailability |
US20060046998A1 (en) * | 2004-08-25 | 2006-03-02 | Fairfield Clinical Trials, Llc | Method of treatment of gastroesophageal reflux disease and laryngopharyngeal reflux disease |
US20060293309A1 (en) * | 2005-03-28 | 2006-12-28 | Dynogen Pharmaceuticals, Inc. | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors |
US7730891B2 (en) * | 2005-10-07 | 2010-06-08 | Lamberg Steven B | Intraoral mandibular advancement device for treatment of sleep disorders |
US20070079833A1 (en) * | 2005-10-07 | 2007-04-12 | Lamberg Steven B | Intraoral mandibular advancement device for treatment of sleep disorders, including snoring, obstructive sleep apnea, and gastroesophageal reflux disease and method for delivering the same |
GB0606426D0 (en) * | 2006-03-30 | 2006-05-10 | Novartis Ag | Benzimidazole derivatives |
ES2602789T3 (es) | 2007-02-09 | 2017-02-22 | Ocera Therapeutics, Inc. | Productos intermedios conectores para la síntesis de moduladores macrocíclicos del receptor de la grelina |
US20080234703A1 (en) * | 2007-03-23 | 2008-09-25 | Ethicon Endo-Surgery, Inc. | Tissue approximation system |
US8852216B2 (en) | 2007-03-23 | 2014-10-07 | Ethicon Endo-Surgery, Inc. | Tissue approximation methods |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
JPS5914460B2 (ja) | 1978-12-27 | 1984-04-04 | 相互薬工株式会社 | H↓2受容体「きつ」抗剤シメチジンの製造法 |
CA1183847A (en) | 1981-10-01 | 1985-03-12 | Georges Van Daele | N-(3-hydroxy-4-piperidinyl)benzamide derivatives |
US5137896A (en) | 1981-10-01 | 1992-08-11 | Janssen Pharmaceutica N.V. | N-(3-hydroxy-4-piperidinyl)benzamide derivatives |
US5057525A (en) | 1981-10-01 | 1991-10-15 | Janssen Pharmaceutica N.V. | Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives |
US4962115A (en) | 1981-10-01 | 1990-10-09 | Janssen Pharmaceutica N.V. | Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives |
SE8204879D0 (sv) | 1982-08-26 | 1982-08-26 | Haessle Ab | Novel chemical intermediates |
US4598123A (en) | 1983-07-14 | 1986-07-01 | Unites States Steel Corporation | Impact modified methyl methacrylate polymer |
IL75400A (en) | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
FI90544C (fi) | 1986-11-13 | 1994-02-25 | Eisai Co Ltd | Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi |
SI8710091A8 (en) | 1987-01-23 | 1996-06-30 | Lek Tovarna Farmacevtskih | Process for obtaining crystalline cimetadine (n-cyano-n'-methyl-n"- (2/(5-methyl-1h-imidazole-4-yl)methylthio/ethyl)-guanidine |
IT1215344B (it) | 1987-01-27 | 1990-02-08 | Dessy S R L Ora Recordati Farm | Procedimento per la preparazione di composti ad attivita' anti-ulcera. |
JPH0623181B2 (ja) | 1987-02-17 | 1994-03-30 | 三井石油化学工業株式会社 | シアノグアニジン誘導体及びその製造法 |
JPH0623180B2 (ja) | 1987-02-17 | 1994-03-30 | 三井石油化学工業株式会社 | シアノグアニジン誘導体及びその製造法 |
US4800162A (en) | 1987-04-01 | 1989-01-24 | Sepracor, Inc. | Method for resolution of steroisomers in multiphase and extractive membrane reactors |
US5057427A (en) | 1988-04-07 | 1991-10-15 | Sepracor, Inc. | Method for resolution of stereoisomers |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
GB8823980D0 (en) | 1988-10-13 | 1988-11-23 | Glaxo Group Ltd | Chemical compounds |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
SE9002043D0 (sv) | 1990-06-07 | 1990-06-07 | Astra Ab | Improved method for synthesis |
DK0617620T3 (da) | 1991-12-21 | 1999-06-07 | Smithkline Beecham Plc | Anvendelse af 5-HT4-modulatorer til fremstilling af et lægemiddel til behandling af blærelidelser |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
CA2139638A1 (en) | 1992-07-07 | 1994-01-20 | Nancy M. Gray | Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders |
CA2139636A1 (en) | 1992-07-07 | 1994-01-20 | Nancy M. Gray | Methods of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
GB9310756D0 (en) | 1993-05-25 | 1993-07-14 | Glaxo Lab Sa | Compositions |
EP0707492A1 (en) | 1993-07-06 | 1996-04-24 | Merck & Co. Inc. | H 2? antagonist-gastrointestinal motility agent combinations |
US5502195A (en) | 1993-11-04 | 1996-03-26 | Slemon; Clarke | Sulfoxide-carboxylate intermediates of omeprazole and lansoprazole |
US5374730A (en) | 1993-11-04 | 1994-12-20 | Torcan Chemical Ltd. | Preparation of omeprazole and lansoprazole |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US5541335A (en) | 1994-07-11 | 1996-07-30 | Torcan Chemical Ltd. | Process for preparing nizatidine |
US5712293A (en) * | 1995-06-07 | 1998-01-27 | Sepracor, Inc. | Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride |
FR2735475B1 (fr) | 1995-06-13 | 1997-07-11 | Synthelabo | Derives de n-((1,4-diazabicyclo(2.2.2)oct-2-yl)methyl) benzamide, leur preparation et leur application en therapeutique |
US5739151A (en) | 1996-07-19 | 1998-04-14 | Sepracor Inc. | Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride |
CN1196681C (zh) * | 1997-07-11 | 2005-04-13 | 詹森药业有限公司 | (+)诺西沙必利用于制备5-ht3和5ht4 介导的疾病的药物中的用途 |
SK19062000A3 (sk) * | 1998-06-15 | 2001-07-10 | Sepracor, Inc. | Použitie (-)-norcisapridu alebo jeho farmaceuticky prijateľnej soli, v podstate bez jeho (+) stereoizoméru, na liečenie apnoe, bulímie a iných porúch |
US6362202B1 (en) * | 1999-03-02 | 2002-03-26 | Sepracor Inc. | Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists |
-
2000
- 2000-02-22 US US09/507,951 patent/US6362202B1/en not_active Expired - Fee Related
- 2000-03-01 HU HU0200151A patent/HUP0200151A3/hu unknown
- 2000-03-01 BR BR0008664-9A patent/BR0008664A/pt not_active IP Right Cessation
- 2000-03-01 CN CN00807003A patent/CN1399572A/zh active Pending
- 2000-03-01 KR KR1020017011176A patent/KR20010108299A/ko not_active Application Discontinuation
- 2000-03-01 EA EA200100937A patent/EA200100937A1/ru unknown
- 2000-03-01 JP JP2000602052A patent/JP2002538104A/ja active Pending
- 2000-03-01 EP EP00915919A patent/EP1156853A2/en not_active Withdrawn
- 2000-03-01 TR TR2001/03128T patent/TR200103128T2/xx unknown
- 2000-03-01 WO PCT/US2000/005167 patent/WO2000051584A2/en not_active Application Discontinuation
- 2000-03-01 SK SK1234-2001A patent/SK12342001A3/sk unknown
- 2000-03-01 AU AU37108/00A patent/AU3710800A/en not_active Abandoned
- 2000-03-01 EE EEP200100459A patent/EE200100459A/xx unknown
- 2000-03-01 NZ NZ513967A patent/NZ513967A/xx not_active Application Discontinuation
- 2000-03-01 CA CA002362488A patent/CA2362488A1/en not_active Abandoned
- 2000-03-01 PL PL00350862A patent/PL350862A1/xx not_active Application Discontinuation
- 2000-03-01 IL IL14516300A patent/IL145163A0/xx unknown
- 2000-03-02 CO CO00015145A patent/CO5150222A1/es unknown
- 2000-03-02 AR ARP000100925A patent/AR022811A1/es unknown
-
2001
- 2001-08-31 NO NO20014229A patent/NO20014229L/no unknown
- 2001-09-21 BG BG105932A patent/BG105932A/xx unknown
-
2002
- 2002-01-10 US US10/041,486 patent/US6548518B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
NO20014229D0 (no) | 2001-08-31 |
WO2000051584A3 (en) | 2001-09-07 |
AR022811A1 (es) | 2002-09-04 |
EA200100937A1 (ru) | 2002-10-31 |
AU3710800A (en) | 2000-09-21 |
EE200100459A (et) | 2002-12-16 |
EP1156853A2 (en) | 2001-11-28 |
US6362202B1 (en) | 2002-03-26 |
NZ513967A (en) | 2001-09-28 |
BG105932A (en) | 2002-12-29 |
SK12342001A3 (sk) | 2002-01-07 |
CO5150222A1 (es) | 2002-04-29 |
CN1399572A (zh) | 2003-02-26 |
WO2000051584A2 (en) | 2000-09-08 |
KR20010108299A (ko) | 2001-12-07 |
NO20014229L (no) | 2001-11-01 |
HUP0200151A3 (en) | 2003-09-29 |
PL350862A1 (en) | 2003-02-10 |
BR0008664A (pt) | 2001-12-18 |
JP2002538104A (ja) | 2002-11-12 |
HUP0200151A2 (en) | 2002-06-29 |
CA2362488A1 (en) | 2000-09-08 |
US6548518B2 (en) | 2003-04-15 |
TR200103128T2 (tr) | 2002-03-21 |
US20020086881A1 (en) | 2002-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ513967A (en) | Methods and compositions using (-) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists | |
IL145162A0 (en) | Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or h2 receptor antagonists | |
IL144611A0 (en) | Indole derivatives and their use as mcp-1 antagonists | |
IL149600A0 (en) | Novel methods and compositions involving opioids and antagonists thereof | |
GB2353523B (en) | Methods and compositions for use in cementing in cold environments | |
EP1115389A4 (en) | ANTAGONISTS AND AGONISTS OF FRUCTOSAMINE OXIDASE | |
HK1082690A1 (en) | Tumor necrosis factor antagonists and their use in endometriosis | |
GB2351285B (en) | Corrosion inhibiting compositions and methods | |
IL144710A0 (en) | Methods and compositions for use in perfusion applications | |
IL141050A0 (en) | Muscarinic agonists and antagonists | |
AU5901900A (en) | Indole and indazole urea-peptoids as thrombin receptor antagonists | |
GB0024946D0 (en) | Improvemnts in time domain reflectometry | |
AU4561700A (en) | Ccr4 antagonists in sepsis | |
EP1242074A4 (en) | NMDA / NR2B ANTAGONISTS BASED ON 5-BENZYL-OCTAHYDROINDOLE AND 6-BENZYL-DECAHYDROQUINOLINE | |
AU5861900A (en) | Receptor agonists and antagonists | |
AU2962200A (en) | Use of agonists or antagonists of mip-3a in therapy | |
AUPQ570100A0 (en) | Beta-alanine derivatives and their use as receptor antagonists | |
IL148323A0 (en) | Prostatic cell line and use thereof to obtain an established prostatic cancer in an animal | |
IL137428A0 (en) | Estrogen agonists and antagonists for multiple indications | |
AU2000236029A1 (en) | Receptor isogenes: polymorphisms in the tissue necrosis factor receptor | |
HK1048075A1 (en) | Use of leptin in inhibition of endothelial cell proliferation. | |
HK1036213A1 (en) | Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors | |
SI1003504T1 (en) | Indole derivatives and their use as mcp-1 antagonists | |
AU4366499A (en) | Improvements in telephone line connection and test modules | |
GB0311582D0 (en) | Corrosion inhibiting compositions and methods |